Petros Pharmaceuticals Stock Investor Sentiment

PTPI Stock  USD 0.27  0.02  6.90%   
Under 61% of Petros Pharmaceuticals' investor base is looking to short. The analysis of the overall investor sentiment regarding Petros Pharmaceuticals suggests that many traders are alarmed. Petros Pharmaceuticals' investing sentiment shows overall attitude of investors towards Petros Pharmaceuticals.
  

Petros Pharmaceuticals Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Petros Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
over three months ago at finance.yahoo.com         
Petros Pharmaceuticals Second Quarter 2024 Earnings Beats Expectations
Yahoo News
over three months ago at news.google.com         
PTPI Stock Earnings Petros Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024 - InvestorPlace
Google News at Macroaxis
over three months ago at news.google.com         
Petros Pharmaceuticals stock hits 52-week low at 0.37 - Investing.com
Google News at Macroaxis
over three months ago at accesswire.com         
Petros Pharmaceuticals Pivotal Statistically Significant Self Selection Study Shows Stronger Results...
news
over three months ago at finance.yahoo.com         
Petros Pharmaceuticals Pivotal Statistically Significant Self Selection Study Shows Stronger Results...
Yahoo News
over three months ago at finance.yahoo.com         
Petros Pharmaceuticals STENDRA Pivotal Consumer Self-Selection Study for Over-the-Counter Access Dem...
Yahoo News
over three months ago at accesswire.com         
Petros Pharmaceuticals STENDRA Pivotal Consumer Self-Selection Study for Over-the-Counter Access Dem...
news
over three months ago at benzinga.com         
EXCLUSIVE Prescription Erectile Dysfunction Market Could Triple If an ED Therapy Is Made Available O...
benzinga news
over three months ago at finance.yahoo.com         
EXCLUSIVE Prescription Erectile Dysfunction Market Could Triple If an ED Therapy Is Made Available O...
Yahoo News
over three months ago at news.google.com         
COMPASS Pathways Petros Pharmaceuticals Critical Contrast - Defense World
Google News at Macroaxis
over six months ago at finance.yahoo.com         
Petros Pharmaceuticals Successfully Completes AI-Integrated Formative Human Factors Study Demonstrat...
Yahoo News
over six months ago at accesswire.com         
Petros Pharmaceuticals Successfully Completes AI-Integrated Formative Human Factors Study Demonstrat...
news
over six months ago at finance.yahoo.com         
Petros Pharmaceuticals Activates Advisory Committee to Help Guide Rx-to-OTC Switch for STENDRA
Yahoo News
over six months ago at investorplace.com         
PTPI Stock Earnings Petros Pharmaceuticals Misses EPS, Misses Revenue for Q1 2024
sbwire news
over six months ago at finance.yahoo.com         
Lemonaid Health Now Offers Prescription ED Medication STENDRA Through Collaboration with Petros Phar...
Yahoo News
Far too much social signal, news, headlines, and media speculation about Petros Pharmaceuticals that are available to investors today. That information is available publicly through Petros media outlets and privately through word of mouth or via Petros internal channels. However, regardless of the origin, that massive amount of Petros data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Petros Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Petros Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Petros Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Petros Pharmaceuticals alpha.

Petros Pharmaceuticals Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Petros Pharmaceuticals Executes Successful Initial Test for App Comprehension as Part of FDA Pathway for Over-the-Counter Access for STENDRA
09/11/2024
2
Insider Trading
09/20/2024
3
Acquisition by John Shulman of 3382416 shares of Petros Pharmaceuticals subject to Rule 16b-3
10/04/2024
4
Acquisition by John Shulman of 1661807 shares of Petros Pharmaceuticals at 1.715 subject to Rule 16b-3
11/08/2024
5
Its Probably Less Likely That Petros Pharmaceuticals, Inc.s CEO Will See A Huge Pay Rise This Year
11/13/2024
6
Acquisition by Gesek Andrew of tradable shares of Petros Pharmaceuticals at 3.99 subject to Rule 16b-3
11/20/2024

Complementary Tools for Petros Stock analysis

When running Petros Pharmaceuticals' price analysis, check to measure Petros Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Petros Pharmaceuticals is operating at the current time. Most of Petros Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Petros Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Petros Pharmaceuticals' price. Additionally, you may evaluate how the addition of Petros Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world